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a greater proportion of patients with sustained resolution of heartburn for up 4 
weeks than omeprazole 20 mg (OR= 1.34; 95%CI: 1.09-1.65). The tolerability and 
safety of esomeprazole were comparable to that of other PPIs. ConClusions: 
Esomeprazole proved to be more effective in healing of erosive GERD than the 
other available PPIs.
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objeCtives: Effects of malnutrition in patients underwent abdominal resection 
surgery (ARS) are often disregarded. This abstract aims to report nutritional sup-
plement (NS) usage in patients underwent abdominal resection surgery (ARS) for 
non-oncological conditions in Turkey using general health insurance (GHI) reim-
bursement database of Social Security Institute. Methods: Turkish GHI system 
has covered 98% of total population of Turkey. Therefore statistics obtained via 
the GHI database are highly representative of the population of Turkey. From GHI 
database, patients who underwent any kind of ARS for non-oncological condi-
tions between 1 January 2009 and 31 December 2013 were included to analy-
sis. Results: In GHI database, 5,787 patients (mean age: 55.0 years, 45.6% female) 
met selection criteria of this abstract. NS was used for 6.6% of the patients dur-
ing hospitalization (median 12.0 days) and NS was used median 2.0 days dur-
ing hospitalization. Mortality rate was 24.2% during hospitalization. Of the 4,384 
discharged patients, 1.2% used NS during outpatient follow-up duration and 
0.8% used NS more than 30 days based on prescribing data. Moreover 97.6% of 
patients who received NS during hospitalization did not continue NS usage dur-
ing outpatient follow-up duration. Median survival durations were 60.0 and 25.1 
months in patients not used NS and used NS, and 12-month survival rates were 
65.0% and 51.0%, respectively. ConClusions: The abstract showed NS usage pat-
terns in patients who underwent ARS for non-oncological conditions in Turkey. 
Malnutrition risk increased with ARS due to type of intervention, but ratio of NS 
usage in daily practice is low and usage duration is relatively short. Moreover 
survival analyses revealed that NS seems to be preferred for complicated patients. 
In conclusion all patients underwent ARS should be evaluated for malnutrition 
and treated accordingly to avoid medical and economic burden.
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objeCtives: Inflammatory Bowel Diseases (IBD), which include Crohn’s disease and 
Ulcerative Colitis, are chronic and life-long conditions. Only symptomatic reliefs 
exist, because the exact cause is not entirely understood. The aim of this study 
was to analyze the healthcare profile and the overall cost of patients with IBD in 
the real clinical practice. Methods: From ARNO Observatory database we car-
ried out a record linkage analysis of disease exemptions, drug prescriptions and 
hospital discharges on 2.664.778 subjects, with available, complete and good qual-
ity data. Hospitalizations and specialist services of every single patient with IBD 
were followed up to 3 years after the accrual (from 01/01/2009 to 31/12/2009), while 
pharmaceutical data were collected up to 4 years. All pharmaceutical prescriptions, 
hospital care (re-hospitalizations, gastro-intestinal surgery, in-hospital mortality), 
diagnostic procedures and their costs (mean patient/year) were analyzed. Results: 
25.427 patients with IBD (50,5% female, mean 56,7±18,7 y.o.) received specific drugs: 
intestinal antinflammatory agents (92,4%), intestinal antinfectives/antibacterials 
for systemic use (49,7%) the most prescribed and immunosoppressants the most 
expensive. As non-specific therapy, patients with IBD received Protonic Pomp 
Inhibitors (62,3%) and antibacterials for systemic use (Penicillins – 58%, Macrolides 
– 39% and Quinolones – 35,8%) prescriptions. Focus on hospitalizations revealed: 
cancer chemotherapy was the first cause of day-hospital admissions and the most 
expensive one; 8,4% of patients had cardiovascular comorbidities; the most fre-
quent re-hospitalizations of men aged 15-44 years; the most prevalent in-hospital 
mortality of women aged ≥ 80 years. The 1-year follow-up costs analysis provided 
that hospitalizations were the most expensive (54,4% /total expenditure, mean cost 
1.168€ /patient) and that specific drugs accounted only for the 9,4%. ConClusions: 
In-hospital cares are the main cost driver for patients with IBD. This must be con-
sidered by LHUs and Physicians when evaluating patient healthcare pathways with 
chronic disease and estimating costs of illness. ARNO Observatory represents an 
important tool to support clinical governance.
GastroINtEstINal dIsordErs – cost studies
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objeCtives: Ulcerative Colitis (UC) exerts significant burden to IBD patients and 
payers. The aim of this study was to estimate the budget impact of vedolizumab in 
moderate/severe UC, from the perspective of the Greek healthcare setting. Methods: 
A Microsoft Excel-based budget impact model was adapted for a hypothetical cohort 
within the total Greek population of IBD patients with moderate/severe UC. The 
budget impact was calculated and presented as incremental drug-acquisition and 
administration costs (input values obtained from National official databases), before 
and up to three years after the introduction of vedolizumab versus standard of care. 
objeCtives: American Diabetes Association and European Association for the 
Study of Diabetes recommend HbA1c levels ≤ 7%, and emphasize initial therapy 
with lifestyle interventions and metformin, addition of medications and transition 
to new regimens within 3-6 months when glycemic goals are not achieved, and 
addition of insulin in patients who remain uncontrolled. This study examines real-
world practice in T2DM patients among US commercially insured patients as it 
relates to guideline recommendations. Methods: A retrospective analysis using 
Truven Health MarketScan® Research Database identified adult T2DM patients 
from 2006-2012 with a minimum follow-up of one year. Patients were categorized 
based on initial therapy: cohort 1 (n= 597,664) - newly diagnosed without treat-
ment in the year prior to or following diagnosis; cohort 2 (n= 342,511) - oral anti-
diabetic drug (OAD) initiators; cohort 3 (n= 99,578) - basal insulin initiators, and 
cohort 4 (n= 62,876) – prandial/mixed insulin initiators. Patients were followed 
for up to 4 years and transitioned out of a cohort once they met the criteria for 
the next cohort. All data were summarized using descriptive statistics. Results: 
Mean age in cohorts 1-4 were 59.1, 56.2, 57.8, and 59.1 years, with approximately 
equal gender distribution. In cohort 1, average HbA1c remained stable, 6.3%, dur-
ing follow-up. 9% of patients initiated treatment with OADs by year 2, and 19% 
by year 4. Those in cohort 2 not achieving HbA1c ≤ 7%, insulin was infrequently 
initiated; approximately 1% transitioned from OADs to insulin. In cohorts 3 and 
4, despite elevated HbA1c values ≥ 8%, the majority of patients were extensively 
treated with OADs prior to insulin initiation. In cohort 4, 69% of patients were 
using basal insulin at year 1, decreasing to 54% by year 4. ConClusions: Findings 
indicate discrepancies in regimens prescribed to T2DM patients in a real-world 
setting despite guideline recommendations to intensify treatment if patients fail 
to achieve glycemic targets.
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objeCtives: As effective management of DM improves clinical outcomes, qual-
ity of care initiatives are being undertaken in many jurisdictions. In the 2012 
Canadian Community Health Survey (CCHS), data were collected on healthcare 
received by those with DM. The objective was to characterize the demographics 
of, and care received by, a contemporary population of adult Canadians with DM; 
and assess whether care quality varied according to age or sex. Methods: Data 
from the subset of 2012 CCHS adult respondents (n= 61,707) asked about diabetes 
care were analyzed. Demographic and clinical characteristics were tabulated, and 
respondents classified as receiving quality diabetic care if they had HbA1c or foot 
exams during the past year, and retinal exams within two years. Predictors of 
receiving quality care were explored using logistic regression, and the frequency 
of physician visits and hospitalizations compared between those receiving, or 
not receiving, quality care. Results: Of the diabetes care cohort (n= 2,458), 48% 
were male, and 75.1% were ≥ 60 years. Eighty percent had a recent HbA1c test, and 
69.2% and 55.2% had a recent eye or foot exam, respectively. Thirty-eight percent 
reported receiving quality diabetes care. While results were similar by sex, some 
variability was observed by age. The percentage receiving quality care ranged from 
30.4% (≥ 80 years), to 40.1% (60-80 years). Age was the only significant predictor; 
the odds of receiving quality care were lower among those aged ≥ 80 years. The fre-
quency of physician visits and hospitalizations did not vary according to receipt of 
quality care. ConClusions: While some guideline monitoring was conducted for 
most respondents, less than half reported receiving all aspects of recommended 
diabetes care. Because these data were self-reported, respondents may have 
received recommended evaluations but been unaware. Opportunities may there-
fore exist for improving the diabetic care of patients, and their awareness of that 
care.
GastroINtEstINal dIsordErs – clinical outcomes studies
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objeCtives: An 8-week course of proton pump inhibitors (PPIs) is the therapy of 
choice for the treatment of gastroesophageal reflux disease (GERD). Esomeprazole, 
the S-isomer of omeprazole, seems to have more potent acid suppression com-
pared to other PPIs due to improved pharmacokinetic profile. The aim of the 
current systematic review was to identify consistent evidence of differences in 
efficacy between esomeprazole and the other available PPIs. Methods: A lit-
erature search of Medline, Embase and Cochrane Library was conducted (last 
search 8/2014) to identify randomized clinical trials comparing rates of endo-
scopic healing and heartburn resolution with esomeprazole versus other PPIs 
(i.e. lansoprazole, omeprazole and pantoprazole) in the treatment of GERD. Search 
and selection of the studies was performed independently by two researchers. 
Only intention-to-treat population reported data were analyzed. Results: Twelve 
RCT studies (3 vs omeprazole, 3 vs lansoprazole and 6 vs pantoprazole) met the 
inclusion criteria and were included in the systematic review. Almost all identi-
fied studies had low or moderate risk of bias (Jadad scale ranging 3-5). One study 
had high risk of bias. The analysis comparing esomeprazole 40 mg with lanso-
prazole 30 mg showed a significant difference in endoscopic healing rate in favor 
of esomeprazole at 4 weeks (OR= 1.25; 95%CI: 1.12-1.40) and 8 weeks (OR= 1.29; 
95%CI: 1.13-1.48). Similarly, esomeprazole 40 mg demonstrated significantly higher 
healing rate when was compared with pantoprazole 40 mg at 4 weeks (OR= 1.33; 
95%CI: 1.15-1.52) and with omeprazole 20 mg at 8 weeks (OR= 1.56; 95%CI: 1.08-
2.25). Data from meta-analysis indicated that esomeprazole 40 mg provided also 
